SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-057046
Filing Date
2024-05-09
Accepted
2024-05-09 16:25:24
Documents
63
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20240331.htm   iXBRL 10-Q 1892698
2 EX-10.1 ntla-ex10_1.htm EX-10.1 42209
3 EX-31.1 ntla-ex31_1.htm EX-31.1 13198
4 EX-31.2 ntla-ex31_2.htm EX-31.2 13200
5 EX-32.1 ntla-ex32_1.htm EX-32.1 8250
  Complete submission text file 0000950170-24-057046.txt   7594710

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20240331.xsd EX-101.SCH 1191187
67 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20240331_htm.xml XML 1201874
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 24931130
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)